Genetic and Epigenetic Biomarkers for B-cell Lymphoma
B 细胞淋巴瘤的遗传和表观遗传生物标志物
基本信息
- 批准号:10433889
- 负责人:
- 金额:$ 36.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAftercareAgeAreaB-Cell LymphomasBehaviorBiological MarkersCancer BiologyCancer PrognosisCategoriesCharacteristicsClinicalClinical TrialsCodeCombined Modality TherapyCyclophosphamideDNA Sequence AlterationDecision MakingDetectionDevelopmentDiseaseDisease ProgressionDoxorubicinExhibitsExtranodalGene MutationGeneticGenetic MarkersGoalsHematologic NeoplasmsHeterogeneityHumanHuman GenomeImmunohistochemistryInternationalInternational Prognostic IndexInvestigationLactate DehydrogenaseLymphomaLymphoma cellMYC geneMalignant NeoplasmsMalignant lymphoid neoplasmMedical centerMicroRNAsModelingMolecularMutationNon-Hodgkin&aposs LymphomaOncogenicOutcomePathogenesisPathway interactionsPatientsPerformance StatusPharmacotherapyPlasmaPlasma CellsPrednisonePrognosisProgression-Free SurvivalsPublic HealthRecurrenceRecurrent diseaseRefractory DiseaseRegimenRelapseResidual stateRiskSamplingSerumSingle Nucleotide PolymorphismSiteSurvival RateTP53 geneTestingTherapy Clinical TrialsTumor Suppressor ProteinsTumor stageUnited StatesUntranslated RNAUntranslated RegionsVariantVincristineWorkbasecancer riskcell free DNAcirculating microRNAclinical applicationclinical practiceclinical predictorsdrug developmentepigenetic markergene translocationimmunohistochemical markersimprovedlarge cell Diffuse non-Hodgkin&aposs lymphomamutantnon-geneticnovelnovel therapeutic interventionnovel therapeuticspatient stratificationpredictive modelingprognosis biomarkerprognosticprognostic modelprognostic significanceprognosticationrelapse predictionrituximabtooltreatment responsetreatment stratificationtumorvirtual
项目摘要
Project Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma in the United
States. Half of all DLBCLs cannot be cured with the standard immuno-chemotherapeutic regimen of rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Currently, the most common tool for
determining DLBLC prognosis is the International Prognostic Index (IPI), which is based on five clinical
characteristics (patient age, tumor stage, serum lactate dehydrogenase concentration, performance status,
and number of extranodal disease sites). Yet DLBCL patients with identical IPI scores exhibit marked variability
in survival, suggesting the presence of significant residual heterogeneity within each IPI category. The TP53
gene encodes the p53 tumor suppressor, the guardian of the human genome. p53 does not function properly
in most human tumors, yet it is inactivated as a direct result of mutations of the TP53 gene in only about 50%
of human tumors. Dysregulation of the p53 pathway is important to the pathogenesis of lymphoid
malignancies, including DLBCL, though mutations in the TP53 coding sequence occur in about 20% of DLBCL
patients. Through our work with the International DLBCL R-CHOP Consortium, which consists of 25 medical
centers, we obtained information leading to the hypothesis we propose to test here: genetic and non-genetic
biomarkers from the TP53 gene alone or in combination with other abnormalities can predict clinical behavior.
In this application, we propose three aims to study the potential of these suspected biomarkers. In Aim #1, we
will determine whether the combination of the IPI and immunohistochemical biomarkers, including p53, is a
more clinically accurate model than the IPI alone for predicting DLBCL prognosis. In Aim #2, we will determine
whether the combination of single-nucleotide variants in the TP53 3' untranslated region and mutations in the
TP53 coding sequence is a biomarker for DLBCL prognosis. In Aim #3, we will determine whether circulating
miRNAs and cell-free DNA are biomarkers for prognosis and relapse detection for DLBCL. Achieving the aims
in this proposal will unravel novel noncoding biomarkers in DLBCL and thereby open a new and unexplored
area of investigation for prognosis, treatment decision making, and possibly drug development for a wide range
of cancers.
项目摘要
弥漫性大B细胞淋巴瘤(DLBCL)是美国最常见的非霍奇金淋巴瘤。
States.所有DLBCL中有一半不能用标准的利妥昔单抗免疫化疗方案治愈,
环磷酰胺、阿霉素、长春新碱和泼尼松(R-CHOP)。目前,最常用的工具
决定DLBLC预后的是国际预后指数(IPI),该指数基于五项临床指标,
特征(患者年龄,肿瘤分期,血清乳酸脱氢酶浓度,体力状态,
和结节病部位的数量)。然而,具有相同IPI评分的DLBCL患者表现出明显的变异性
在生存率方面,表明在每个IPI类别中存在显著的残余异质性。的tp 53
基因编码p53肿瘤抑制因子,人类基因组的守护者。p53不能正常工作
在大多数人类肿瘤中,TP 53基因突变的直接结果是失活,但只有约50%的人失活。
人类肿瘤。p53通路的失调在淋巴结转移的发病机制中很重要。
恶性肿瘤,包括DLBCL,尽管TP 53编码序列突变发生在约20%的DLBCL中
患者通过我们与国际DLBCL R-CHOP联盟的合作,该联盟由25个医疗机构组成,
中心,我们获得的信息导致我们提出的假设,在这里测试:遗传和非遗传
来自TP 53基因的生物标志物单独或与其它异常组合可以预测临床行为。
在本申请中,我们提出了三个目标来研究这些可疑生物标志物的潜力。在目标#1中,我们
将确定IPI和免疫组织化学生物标志物(包括p53)的组合是否是一种免疫反应。
在预测DLBCL预后方面,IPI模型比单独使用IPI模型在临床上更准确。在目标#2中,我们将确定
TP 53 3 3'非翻译区中的单核苷酸变体和
TP 53编码序列是DLBCL预后的生物标志物。在目标#3中,我们将确定是否循环
miRNA和游离DNA是DLBCL预后和复发检测的生物标志物。实现目标
这项提案将揭示DLBCL中新的非编码生物标志物,从而开辟一个新的和未探索的
研究领域的预后,治疗决策,并可能药物开发的广泛范围
癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEN H YOUNG其他文献
KEN H YOUNG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEN H YOUNG', 18)}}的其他基金
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
B 细胞淋巴瘤的遗传和表观遗传生物标志物
- 批准号:
10048471 - 财政年份:2020
- 资助金额:
$ 36.09万 - 项目类别:
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
B 细胞淋巴瘤的遗传和表观遗传生物标志物
- 批准号:
10190849 - 财政年份:2020
- 资助金额:
$ 36.09万 - 项目类别:
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
B 细胞淋巴瘤的遗传和表观遗传生物标志物
- 批准号:
10674524 - 财政年份:2020
- 资助金额:
$ 36.09万 - 项目类别:
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
B 细胞淋巴瘤的遗传和表观遗传生物标志物
- 批准号:
9814315 - 财政年份:2019
- 资助金额:
$ 36.09万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 36.09万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 36.09万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 36.09万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 36.09万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 36.09万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 36.09万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 36.09万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 36.09万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 36.09万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 36.09万 - 项目类别: